{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:55:13Z","timestamp":1761519313842,"version":"3.44.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ando.2020.11.010","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T10:44:14Z","timestamp":1607165054000},"page":"8-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Corticotropic insufficiency in a monocentric prospective cohort of patients with lung cancer treated with nivolumab: Prevalence and etiology"],"prefix":"10.1016","volume":"82","author":[{"given":"Roxane","family":"Ducloux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Yves","family":"Tavernier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perrine","family":"Wojewoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flora","family":"Toullet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Romanet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Averous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2019","series-title":"Estimations nationales de l\u2019incidence et de la mortalit\u00e9 par cancer en France m\u00e9tropolitaine entre 1990 et 2018. \u00c9tude \u00e0 partir des registres des cancers du r\u00e9seau Francim. R\u00e9sultats pr\u00e9liminaires. Synth\u00e8se","author":"Defossez","key":"10.1016\/j.ando.2020.11.010_bib0090"},{"key":"10.1016\/j.ando.2020.11.010_bib0095","first-page":"735","article-title":"Cancers du poumon\u00a0: quoi de neuf\u00a0?","volume":"32","author":"Abbar","year":"2018","journal-title":"Rev Prat Med Gen"},{"key":"10.1016\/j.ando.2020.11.010_bib0100","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ando.2020.11.010_bib0105","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy -immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ando.2020.11.010_bib0110","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2020.11.010_bib0115","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Antiprogrammed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ando.2020.11.010_bib0120","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ando.2020.11.010_bib0125","doi-asserted-by":"crossref","first-page":"9055a","DOI":"10.1200\/jco.2015.33.15_suppl.9055","article-title":"Survival, biomarker, andtoxicity analysis of nivolumab (NIVO) in patients that progressed on ipilimumab (IPI)","volume":"33","author":"Weber","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ando.2020.11.010_bib0130","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","author":"Sznol","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ando.2020.11.010_bib0135","unstructured":"OPDIVO (nivolumab) Prescribing Information (Revised 10\/2016), http:\/\/packageinserts.bms.com\/pi\/pi_opdivo.pdf [accessed October 21, 2016]."},{"key":"10.1016\/j.ando.2020.11.010_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ando.2017.12.001","article-title":"SFE\/SFEDP adrenal insufficiency French consensus: introduction and handbook","volume":"79","author":"Reznik","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.ando.2020.11.010_bib0145","article-title":"Endocrine-related adverse events related to immune checkpoint inhibitors: proposed algorithms for management","author":"Del Rivero","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ando.2020.11.010_bib0150","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1530\/EJE-19-0238","article-title":"Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis","volume":"181","author":"Faje","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2020.11.010_bib0155","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1530\/EJE-17-0810","article-title":"The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma","volume":"178","author":"Scott","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2020.11.010_bib0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ando.2018.07.008","article-title":"Expert opinion on pituitary complications in immunotherapy","author":"Briet","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.ando.2020.11.010_bib0165","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2020.11.010_bib0170","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study","volume":"21","author":"Min","year":"2015","journal-title":"Clin Cancer Res"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426620313135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426620313135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:53:02Z","timestamp":1757717582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426620313135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0003426620313135"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2020.11.010","relation":{},"ISSN":["0003-4266"],"issn-type":[{"type":"print","value":"0003-4266"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Corticotropic insufficiency in a monocentric prospective cohort of patients with lung cancer treated with nivolumab: Prevalence and etiology","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2020.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}